Article
A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations.
ESMO open - 1 Apr 2023
Villaruz L C, Wang X, Bertino E M, Gu L, Antonia S J, Burns T F, Clarke J, Crawford J, Evans T L, Friedland D M, Otterson G A, Ready N E, Wozniak A J, Stinchcombe T E
Abstract excerpt
BACKGROUND: For patients with stage IV non-small-cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions and exon 21 L858R mutations, osimertinib is the standard of care. Investigating the activity and safety of osimertinib in patients with EGFR exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations is of clinical interest. PATIENTS AND METHODS: Patients with stage IV non-small-cell lung...
Topics
Join the communities discussing this publication.